{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:31:08Z","timestamp":1794990668542,"version":"4.9.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R56AG075744"],"award-info":[{"award-number":["R56AG075744"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG038791"],"award-info":[{"award-number":["R01AG038791"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG077557"],"award-info":[{"award-number":["RF1AG077557"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG071756"],"award-info":[{"award-number":["R01AG071756"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U19AG063911"],"award-info":[{"award-number":["U19AG063911"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG073482"],"award-info":[{"award-number":["R01AG073482"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U24AG057437"],"award-info":[{"award-number":["U24AG057437"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01AG078457"],"award-info":[{"award-number":["1R01AG078457"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015595","name":"GHR Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08AG083050"],"award-info":[{"award-number":["K08AG083050"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R25NS070680"],"award-info":[{"award-number":["R25NS070680"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer&apos;s Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021066","name":"Gates Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016608","name":"Rainwater Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.neurot.2024.e00321","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:20:06Z","timestamp":1706185206000},"page":"e00321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Disentangling tau: One protein, many therapeutic approaches"],"prefix":"10.1016","volume":"21","author":[{"given":"Courtney","family":"Lane-Donovan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00321_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer's disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurot.2024.e00321_bib2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/alz.12452","article-title":"Current directions in tau research: highlights from Tau 2020","volume":"18","author":"Sexton","year":"2022","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00321_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-021-00476-x","article-title":"Cellular and pathological heterogeneity of primary tauopathies","volume":"16","author":"Chung","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurot.2024.e00321_bib4","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A\u00a0protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00321_bib5","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.1504081112","article-title":"Tau stabilizes microtubules by binding at the interface between tubulin heterodimers","volume":"112","author":"Kadavath","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00321_bib6","doi-asserted-by":"crossref","first-page":"9548","DOI":"10.1073\/pnas.1633508100","article-title":"Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease","volume":"100","author":"Panda","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00321_bib7","article-title":"Role of tau as a microtubule-associated protein: structural and functional aspects","volume":"10","author":"Barbier","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00321_bib9","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1073\/pnas.89.10.4378","article-title":"Primary structure of high molecular weight tau present in the peripheral nervous system","volume":"89","author":"Couchie","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00321_bib10","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1073\/pnas.89.5.1983","article-title":"Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system","volume":"89","author":"Goedert","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00321_bib11","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0052-23.2023","article-title":"Big tau: what we know, and we need to know","volume":"10","author":"Fischer","year":"2023","journal-title":"ENeuro"},{"key":"10.1016\/j.neurot.2024.e00321_bib12","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.1998.70041346.x","article-title":"Splicing of a regulated exon reveals additional complexity in the axonal microtubule-associated protein tau","volume":"70","author":"Wei","year":"1998","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00321_bib13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/jcb.20029","article-title":"Tau isoforms which contain the domain encoded by exon 6 and their role in neurite elongation","volume":"91","author":"Luo","year":"2004","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.neurot.2024.e00321_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1471-4159.2004.02508.x","article-title":"Novel isoforms of tau that lack the microtubule-binding domain","volume":"90","author":"Luo","year":"2004","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00321_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000440840","article-title":"Genetic disorders with tau pathology: a review of the literature and report of two patients with tauopathy and positive family histories","volume":"16","author":"Tacik","year":"2016","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.neurot.2024.e00321_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbadis.2004.08.007","article-title":"Mutations causing neurodegenerative tauopathies","volume":"1739","author":"Goedert","year":"2005","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"10.1016\/j.neurot.2024.e00321_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5\u2019-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2024.e00321_bib18","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1093\/hmg\/dds161","article-title":"Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases","volume":"21","author":"Coppola","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00321_bib19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ana.10163","article-title":"Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation","volume":"51","author":"Hayashi","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00401-003-0734-x","article-title":"The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy","volume":"106","author":"Hogg","year":"2003","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00321_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076409","article-title":"A\u00a0novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function","volume":"8","author":"Iyer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2024.e00321_bib22","unstructured":"A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. | ALZFORUM n.d. https:\/\/www.alzforum.org\/papers\/novel-tau-mutation-s320f-causes-tauopathy-inclusions-similar-those-picks-disease (accessed September 14, 2023)."},{"key":"10.1016\/j.neurot.2024.e00321_bib23","first-page":"1","article-title":"Mutations in \u03b1-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases","volume":"18","author":"Sampognaro","year":"2023","journal-title":"Mol Neurodegener"},{"issue":"Pt 5","key":"10.1016\/j.neurot.2024.e00321_bib24","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/brain\/123.5.880","article-title":"Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations","volume":"123","author":"Stanford","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00321_bib25","first-page":"122","article-title":"Genetics of progressive supranuclear palsy","volume":"8","author":"Im","year":"2015","journal-title":"J\u00a0Mov Disord"},{"key":"10.1016\/j.neurot.2024.e00321_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00401-017-1693-y","article-title":"Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia","volume":"133","author":"Yokoyama","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00321_bib27","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/jama.286.18.2245","article-title":"Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease","volume":"286","author":"Martin","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2024.e00321_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/hmg\/8.4.711","article-title":"Association of an extended haplotype in the tau gene with progressive supranuclear palsy","volume":"8","author":"Baker","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00321_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00327","article-title":"The MAPT H1 haplotype is a risk factor for Alzheimer's disease in APOE \u03b54 non-carriers","volume":"11","author":"S\u00e1nchez-Juan","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/jmg.2005.031377","article-title":"Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration","volume":"42","author":"Pittman","year":"2005","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.neurot.2024.e00321_bib31","first-page":"17","article-title":"17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson's disease are associated with LRRC37A\/2 expression in astrocytes","author":"Bowles","year":"2022","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurot.2024.e00321_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3233\/JAD-161149","article-title":"Recent progress in Alzheimer's disease research, part 2: genetics and epidemiology","volume":"57","author":"Robinson","year":"2017","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neurot.2024.e00321_bib33","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neurot.2024.e00321_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.595532","article-title":"Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation","volume":"11","author":"Alquezar","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib35","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1096\/fasebj.9.15.8529836","article-title":"Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases","volume":"9","author":"Trojanowski","year":"1995","journal-title":"Faseb J"},{"key":"10.1016\/j.neurot.2024.e00321_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/abbi.1998.0813","article-title":"Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules","volume":"357","author":"Sengupta","year":"1998","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00321_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-021-00460-5","article-title":"\u201cDon't Phos over Tau\u201d: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies","volume":"16","author":"Xia","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurot.2024.e00321_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neulet.2018.11.011","article-title":"Phosphorylation of serine 305 in tau inhibits aggregation","volume":"692","author":"Strang","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurot.2024.e00321_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41672-1","article-title":"Acetylation discriminates disease-specific tau deposition","volume":"14","author":"Chakraborty","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00321_bib40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.str.2023.05.020","article-title":"Disease-associated patterns of acetylation stabilize tau fibril formation","volume":"31","author":"Li","year":"2023","journal-title":"Structure"},{"key":"10.1016\/j.neurot.2024.e00321_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22501-9","article-title":"Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice","volume":"12","author":"Caballero","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00321_bib42","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00321_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-5793(02)02228-7","article-title":"Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease","volume":"512","author":"Liu","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.neurot.2024.e00321_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.702788","article-title":"Human tau isoforms and proteolysis for production of toxic tau fragments in neurodegeneration","volume":"15","author":"Boyarko","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib45","doi-asserted-by":"crossref","first-page":"13812","DOI":"10.1074\/jbc.RA120.012587","article-title":"Truncation of Tau selectively facilitates its pathological activities","volume":"295","author":"Gu","year":"2020","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00321_bib46","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00321_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00121","article-title":"Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. Extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer's disease","volume":"11","author":"Barth\u00e9lemy","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib48","first-page":"1866","article-title":"N-terminal tau truncation in the pathogenesis of Alzheimer's disease (AD): developing a novel diagnostic and therapeutic approach","author":"Amadoro","year":"2020","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"key":"10.1016\/j.neurot.2024.e00321_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39328-1","article-title":"Specific post-translational modifications of soluble tau protein distinguishes Alzheimer's disease and primary tauopathies","volume":"14","author":"Kyalu Ngoie Zola","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00321_bib50","doi-asserted-by":"crossref","unstructured":"Chen D, Drombosky KW, Hou Z, Sari L, Kashmer OM, Ryder BD, et\u00a0al. Tau local structure shields an amyloid-forming motif and controls aggregation propensity n.d. https:\/\/doi.org\/10.1038\/s41467-019-10355-1.","DOI":"10.1038\/s41467-019-10355-1"},{"key":"10.1016\/j.neurot.2024.e00321_bib51","doi-asserted-by":"crossref","first-page":"102163","DOI":"10.1016\/j.jbc.2022.102163","article-title":"Seed-competent tau monomer initiates pathology in a tauopathy mouse model","author":"Mirbaha","year":"2022","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00321_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00401-021-02301-7","article-title":"Tau strains shape disease","volume":"142","author":"Vaquer-Alicea","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00321_bib53","article-title":"Transmission of tauopathy strains is independent of their isoform composition","volume":"11","author":"He","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00321_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00698","article-title":"Propagation of tau via extracellular vesicles","volume":"13","author":"P\u00e9rez","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib55","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.neurot.2024.e00321_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(20)30394-X","article-title":"Genetic determinants\u00a0of\u00a0survival in progressive supranuclear palsy: a genome-wide association study","volume":"20","author":"Msc","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/science.add6696","article-title":"TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease","volume":"381","author":"Zhang","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.neurot.2024.e00321_bib58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib59","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-019-0470-7","article-title":"18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes","volume":"11","author":"Tsai","year":"2019","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.neurot.2024.e00321_bib60","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/acn3.290","article-title":"Plasma neurofilament light chain predicts progression in progressive supranuclear palsy","volume":"3","author":"Rojas","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1212\/CON.0000000000000698","article-title":"Behavioral variant frontotemporal dementia","volume":"25","author":"Seeley","year":"2019","journal-title":"Continuum"},{"key":"10.1016\/j.neurot.2024.e00321_bib62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00005072-199701000-00007","article-title":"Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain","volume":"56","author":"Pei","year":"1997","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib63","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/cells10020262","article-title":"Mechanisms and therapeutic implications of GSK-3 in treating neurodegeneration","volume":"10","author":"Rippin","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neurot.2024.e00321_bib64","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1192\/bjp.2019.76","article-title":"Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial","volume":"215","author":"Forlenza","year":"2019","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.neurot.2024.e00321_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2016.04.021","article-title":"Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy","volume":"146","author":"Leclair-Visonneau","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00321_bib66","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A\u00a0phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2024.e00321_bib67","first-page":"75","article-title":"A\u00a0phase II trial of tideglusib in Alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J\u00a0Alzheim Dis"},{"key":"10.1016\/j.neurot.2024.e00321_bib68","article-title":"Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward","volume":"14","author":"Arciniegas Ruiz","year":"2021","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib69","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1523\/JNEUROSCI.4162-03.2004","article-title":"Phosphorylation of tau by Fyn: implications for Alzheimer's disease","volume":"24","author":"Lee","year":"2004","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00040","article-title":"Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn","volume":"7","author":"Xia","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib71","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1073\/pnas.96.2.435","article-title":"PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A","volume":"96","author":"Tezuka","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00321_bib72","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-020-00976-9","article-title":"Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy","volume":"8","author":"Tang","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00321_bib73","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nn.3178","article-title":"Alzheimer amyloid-\u03b2 oligomer bound to postsynaptic prion protein activates Fyn to impair neurons","volume":"15","author":"Um","year":"2012","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib74","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2024.e00321_bib75","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial","volume":"76","author":"Van Dyck","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib76","article-title":"Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-\u03b2 toxicity and network hyperexcitability","author":"Roth","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2024.e00321_bib77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nchembio.797","article-title":"Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation","volume":"8","author":"Yuzwa","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.neurot.2024.e00321_bib78","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-020-0616-4","article-title":"PET quantification of brain O-GlcNAcase with [18F]LSN3316612 in healthy human volunteers","volume":"10","author":"Lee","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.neurot.2024.e00321_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/alz.040558","article-title":"Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: translation from rat to human","volume":"16","author":"Shcherbinin","year":"2020","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neurot.2024.e00321_bib80","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1073\/pnas.1808845116","article-title":"\u03b1-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease","volume":"116","author":"Levine","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00321_bib81","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","article-title":"NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model","volume":"34","author":"Shiryaev","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2024.e00321_bib82","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib83","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","article-title":"A\u00a0double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 Weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.neurot.2024.e00321_bib84","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3233\/JAD-190465","article-title":"In vivo validation of a small molecule inhibitor of tau self-association in htau mice","volume":"73","author":"Davidowitz","year":"2020","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neurot.2024.e00321_bib85","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2024.e00321_bib86","doi-asserted-by":"crossref","first-page":"11024","DOI":"10.1074\/jbc.M112.436006","article-title":"Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation","volume":"288","author":"Crowe","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00321_bib87","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose Leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neurot.2024.e00321_bib88","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207663","article-title":"Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00321_bib89","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00401-021-02318-y","article-title":"Tau immunotherapy is associated with glial responses in FTLD-tau","volume":"142","author":"Kim","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00321_bib90","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00321_bib91","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01616412.2021.2022921","article-title":"Pathogenic cis p-tau levels in CSF reflects severity of traumatic brain injury","volume":"44","author":"Mohsenian Sisakht","year":"2022","journal-title":"Neurol Res"},{"key":"10.1016\/j.neurot.2024.e00321_bib92","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamaneurol.2016.2027","article-title":"Potential of the antibody against cis-phosphorylated tau in the early diagnosis, treatment, and prevention of Alzheimer disease and brain injury","volume":"73","author":"Lu","year":"2016","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00321_bib93","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-021-01465-9","article-title":"Tau-targeting antibody therapies: too late, wrong epitope or wrong target?","volume":"27","author":"Jabbari","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00321_bib94","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00321_bib95","doi-asserted-by":"crossref","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimer's Res Ther"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00321_bib96","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nature Aging"},{"key":"10.1016\/j.neurot.2024.e00321_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2024.e00321_bib98","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00321_bib99","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00321_bib100","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.neurot.2024.e00321_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00321_bib102","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00321_bib104","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00321_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02369-8","article-title":"Brain organoid: a 3D technology for investigating cellular composition and interactions in human neurological development and disease models in vitro","volume":"12","author":"Agboola","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.neurot.2024.e00321_bib106","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.stem.2015.09.001","article-title":"Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects","volume":"17","author":"Mertens","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neurot.2024.e00321_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.00011","article-title":"Differences between human and murine tau at the N-terminal end","volume":"12","author":"Hern\u00e1ndez","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2024.e00321_bib108","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A\u03b2 and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00321_bib109","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1471-4159.2006.04139.x","article-title":"Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert","volume":"99","author":"Engel","year":"2006","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00321_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: the past and future of clinical trials","author":"Boxer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2024.e00321_bib111","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00321_bib112","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:45:57Z","timestamp":1778831157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1878747924000072"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00321","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disentangling tau: One protein, many therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00321"}}